Results 221 to 230 of about 222,217 (297)

Zanubrutinib versus fludarabine, cyclophosphamide and rituximab in fit, treatment-naïve patients with chronic lymphocytic leukemia: a matching-adjusted indirect comparison. [PDF]

J Comp Eff Res
Munir T, Barnieh L, Mohseninejad L, Xu S, Jevdjevic M, Bouwmeester W, Yang K.   +6 more
europepmc   +1 more source

Warm autoimmune haemolytic anaemia in Taiwan: A population‐based study of epidemiology, treatment patterns, survival and healthcare utilisation (2017–2022)

British Journal of Haematology, EarlyView.
Summary To describe the epidemiology, treatment patterns, overall survival (OS) and healthcare resource use among patients with warm autoimmune haemolytic anaemia (wAIHA) in Taiwan, adult patients with ≥1 diagnosis code for autoimmune haemolytic anaemia (AIHA) with record of wAIHA‐related treatments between 2017 and 2022 were retrospectively identified
Hsiao‐Wen Kao, Shu‐Chen Chang, Dae Young Yu, Tse‐Chih Chou, I‐Ching Tsai, Ann Leon, Alexis Krumme, David Bin‐Chia Wu, Chee Jen Chang   +8 more
wiley   +1 more source

Gonadotropin-releasing hormone agonists during cyclophosphamide for ovarian protection in systemic lupus erythematosus. [PDF]

Reprod Fertil
Maiorano MFP, Cormio G, Loizzi V, Maiorano BA, Corrado G, Silvestris E.   +5 more
europepmc   +1 more source

Ibrutinib versus allogeneic haematopoietic stem cell transplant in relapsed/refractory del(17p) chronic lymphocytic leukaemia/small lymphocytic lymphoma

British Journal of Haematology, EarlyView.
After adjusting for confounders, the ibrutinib cohort had significantly better overall survival (adjusted hazard ratio, 0.39; 95% confidence interval, 0.23–0.68; p = 0.0008) than the allogeneic haematopoietic stem cell transplantation (alloHSCT) cohort.
Farrukh T. Awan, Ran Liu, Hsin‐Hui Huang, Matthew Bye, Kwang Woo Ahn, Gabriel Krigsfeld, Anat Raz, Heather Wolfe, Mehdi Hamadani   +8 more
wiley   +1 more source

The hidden mystery behind the Hilar shadows. [PDF]

Lung India
Sivaselvi C, Iyer H, Yadav T, Gopalakrishnan M.   +3 more
europepmc   +1 more source

A phase IIa study of the anti‐PD‐L1 antibody avelumab in relapsed/refractory PTCL: The AVAIL‐T trial

British Journal of Haematology, EarlyView.
The AVAIL‐T study, the first evaluation of programmed death ligand 1 (PD‐L1) blockade in relapsed/refractory peripheral T‐cell lymphomas (PTCL), demonstrated limited single agent activity with durable responses seen in a minority. Circulating tumour DNA revealed distinct mutational dynamics and mass cytometry identified perturbed T‐cell subsets ...
Matthew J. Ahearne, Matthew A. Timmins, Charlotte Gaskell, Aimee Jackson, Clare Morland, Sonia Fox, Louise Hopkins, Nadia Nawaz, Susann Lehmann, Marc Wadsley, Caroline Cowley, Jacqueline Shaw, Naeem Khan, Nagesh Kalakonda, Christopher Trethewey, Ram Malladi, Paul Fields, Dima El Sharkawi, Michael Quinn, Nimish Shah, Andrew Davies, Kim Linton, Pam McKay, Rod Johnson, Simon D. Wagner, David Lewis, Graham P. Collins, Christopher P. Fox, Kate Cwynarski   +28 more
wiley   +1 more source

Daratumumab Treatment in Severe Anti-NMDAR Encephalitis: Two Case Reports and Literature Review. [PDF]

Neurol Neuroimmunol Neuroinflamm
Ammar N, Uginet M, De Stefano P, Quintard H, Samii K, Seebach JD, Dalmau J, Lalive PH.   +7 more
europepmc   +1 more source

Reduced‐dose versus standard‐dose total body irradiation before allogeneic haematopoietic stem cell transplantation in adults with acute lymphoblastic leukaemia

British Journal of Haematology, EarlyView.
Summary Comparative data on reduced‐dose (8 Gy) versus standard‐dose (12 Gy) total body irradiation (TBI) before allogeneic haematopoietic stem cell transplantation (allo‐HSCT) for adults with acute lymphoblastic leukaemia (ALL) remain limited. We retrospectively analysed 101 adults undergoing first allo‐HSCT between 1999 and 2024 after 8 Gy or 12 Gy ...
Isabella Gruber, Matthias Edinger, Hendrik Poeck, Elisabeth Meedt, Ernst Holler, Wolfgang Herr, Oliver Koelbl, Daniel Wolff   +7 more
wiley   +1 more source